Navigation Links
Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Body's Own Naturally Occurring Stem Cells
Date:1/24/2008

, is the kind of product the medical industry is looking for."

Derma Sciences obtained the rights to DSC127 via license with the University of Southern California, and has signed a clinical services agreement with U.S. Biotest. The scope of the agreement covers pre-study services, study management, clinical operations, data management and medical writing.

Early testing of DSC127 demonstrated that its healing powers may work by promoting the recruitment of mesenchymal stem cells to sites of tissue injury. Mesenchymal stem cells are integral to the creation of several tissue types including skin, beginning in the fetal stages of development.

DSC127 is a novel angiotensin analog that was shown in various animal models to promote healing and reduce scar formation. As a person ages and gets beyond the age of rapid growth, the number of his or her mesenchymal stem cells greatly diminishes. However, administration of DSC127 at the site of tissue injury may promote the recruitment of mesenchymal stem cells in numbers that support the rapid healing of tissue. Application of DSC127 in various animal models has resulted in the increased pace of angiogenesis, as well as increased keratinocyte and extracellular matrix production, all key drivers for dermal repair.

U.S. Biotest, founded by Drs. Gere diZerega and Kathleen Rodgers, maintains an expertise in the licensed compound and has extensive capability in the development of devices and pharmaceutical agents. Drs. diZerega and Rodgers have previously been involved in the development of 4 medical products that have received FDA approval and 7 medical products that are marketed worldwide. Regarding DSC127, they have directed all pre-clinical work, including compound development, manufacturing validation, toxicology studies, successful National Institutes of Health (NIH) grant submissions, acquisition of an Investigational New Drug (IND), and completion of a Phase I clinical trial.

Regarding Derm
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
2. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
3. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
7. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
8. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. U.S. Patent Office Rejects Key HIV/AIDS Drug Patents at PUBPAT Request: Government Finds Prior Art Submitted By PUBPAT Invalidates All of Gilead Sciences Claims
11. Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- Misonix, Inc. (NASDAQ: MSON ), an international ... innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and ... financial results for the first quarter fiscal year 2015 ... a conference call that same day, Thursday, November 6, ... Interested parties can access the conference ...
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
(Date:10/30/2014)... , Oct. 30, 2014  Electronic health records ... a result of government initiatives and the considerable ... providers have invested over the past five years. ... health IT, and U.S. clinicians use them on ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
... Aug. 8, 2011 Insmed Incorporated (Nasdaq CM: INSM), a ... six-months ended June 30, 2011. Key Recent ... of data from the open-label phase 2 study of Arikace™ ... (CF) patients with Pseudomonas lung infections ...
... (NYSE Amex: ANX ) today reported financial results ... we head into the second half of the year, we ... into the U.S. market, should it be approved on or ... Brian M. Culley, Chief Executive Officer of ADVENTRX.  "Having a ...
Cached Medicine Technology:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 2Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 3Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 4Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 5Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 6Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 7Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2011 8ADVENTRX Reports Second Quarter 2011 Financial Results 2ADVENTRX Reports Second Quarter 2011 Financial Results 3ADVENTRX Reports Second Quarter 2011 Financial Results 4ADVENTRX Reports Second Quarter 2011 Financial Results 5ADVENTRX Reports Second Quarter 2011 Financial Results 6ADVENTRX Reports Second Quarter 2011 Financial Results 7
(Date:10/31/2014)... apnea may make it hard for you to remember simple ... your house keys, a small study suggests. Tests on ... -- called spatial memory -- was impaired when sleep apnea ... of sleep weren,t affected. REM sleep is the deepest level ... for the first time that sleep apnea, an increasingly common ...
(Date:10/31/2014)... Hopkins engineers have invented a lab device to give ... complex way that tumor cells spread through the body, ... shedding light on precisely how tumor cells travel, the ... check. , The inventors, from the university,s Whiting School ... details and images from their new system recently in ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
(Date:10/31/2014)... October 31, 2014 Phoenix dentist , ... treatments for November. Whether patients simply need routine care or ... better time than now to get that necessary care. The ... put off routine and even essential treatments due to financial ... substantial savings on any treatments offered by the team at ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... PhD, FNP Join Together to Raise Awareness of Common, ... Fibromyalgia is often called an "invisible" illness because ... sick. However, something as simple as a hug ... fibromyalgia is one of the most common chronic, widespread ...
... China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, Inc., ... "Company"),(which recently changed its name from Genesis ... U.S. pharmaceutical company with its,principal operations in ... today,that its management will present at the ...
... Online Resource, YouCanBeTheOne.com, Recommended to Help Guide Important Conversations ... YORK, May 12 The multi-disciplinary expert consortium known ... calling upon family and friends to proactively start a ... physician at the first sign of possible Alzheimer,s disease ...
... Commissioned by Non-Profit Identifies Unmet Needs of CaregiversWASHINGTON, May ... Wellness Community revealed many Americans who provide support to ... as a caregiver. In fact, only 20 percent ... estimate of 60 percent. This year, it is projected ...
... and Pharma on PanelWALTHAM, Mass., May 12 ... ) announced today that CEO Lewis H. Bender will ... Markers in Drug Development: How Personalized Medicine is Evolving ... May 18-21, 2009 in Atlanta, GA. The panel ...
... DOYLESTOWN, Pa., May 12 The Quigley Corporation (Nasdaq: ... today announced that the world,s leading independent proxy advisory ... Glass Lewis & Co. have recommended that stockholders vote ... investor Ted Karkus, solicitation seeking control of the Board ...
Cached Medicine News:Health News:VIDEO from Medialink, the National Fibromyalgia Association and Pfizer: The Painful Truth about Fibromyalgia 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 2Health News:Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 2Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 3Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 4Health News:Experts Urge Family Members and Friends to Seek Immediate Intervention for Their Loved Ones Who May Have Alzheimer's Disease (AD) 5Health News:Cancer Caregiver Distress Unrecognized and Under Reported 2Health News:Cancer Caregiver Distress Unrecognized and Under Reported 3Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 2Health News:Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 2Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 3Health News:Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan 4
3.5 mm blade. Round handle. Designated most popular model or size....
7 mm curved blade. Round handle....
1.5 mm long blade. Square handle....
Double-ended. 0.9 mm x 1 mm blade. Angled at 90 and 120 degrees. Round handle. Designated most popular model or size....
Medicine Products: